Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other 1Gynecologic 1

Conditions

Endometrial Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Obesity 1Fallopian Tube Neoplasms 1Endometrial Cancer Recurrent 1Disease 1Carcinosarcoma 1Breast Neoplasms, Male 1

Interventions

Specimen Handling 6Paclitaxel 6Magnetic Resonance Spectroscopy 5Nivolumab 4Carboplatin 4Biopsy 4pembrolizumab 2olaparib 2ceralasertib 2Taxes 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pamiparib 1durvalumab 1cobimetinib 1cediranib 1cabozantinib 1belinostat 1atezolizumab 1X-Rays 1Tissue Banks 1TIC10 compound 1Ipilimumab 1Immunoglobulin G 1Ifosfamide 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × TIC10 compound × Gynecologic × Clear all
NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
58 enrolled
GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡